Liver Cancer (Mar 2023)

Definitive liver radiotherapy for intrahepatic cholangiocarcinoma with extrahepatic metastases

  • Brian De,
  • Rituraj Upadhyay,
  • Kaiping Liao,
  • Tiffany Kumala,
  • Christopher Shi,
  • Grace Dodoo,
  • Joseph Abi Jaoude,
  • Kelsey L. Corrigan,
  • Gohar S. Manzar,
  • Kathryn E. Marqueen,
  • Vincent Bernard,
  • Sunyoung S Lee,
  • Kanwal P.S. Raghav,
  • Jean-Nicolas Vauthey,
  • Ching-Wei Tzeng,
  • Hop S. Tran Cao,
  • Grace Lee,
  • Jennifer Wo,
  • Theodore S Hong,
  • Christopher H Crane,
  • Bruce D. Minsky,
  • Grace L. Smith,
  • Emma B. Holliday,
  • Cullen M. Taniguchi,
  • Albert C. Koong,
  • Prajnan Das,
  • Milind Javle,
  • Ethan B. Ludmir,
  • Eugene Koay

DOI
https://doi.org/10.1159/000530134

Abstract

Read online

Introduction: Tumor-related liver failure (TRLF) is the most common cause of death in patients with intrahepatic cholangiocarcinoma (ICC). Though we previously showed that liver radiotherapy (L-RT) for locally advanced ICC is associated with less frequent TRLF and longer overall survival (OS), the role of L-RT for patients with extrahepatic metastatic disease (M1) remains undefined. We sought to compare outcomes for M1 ICC patients treated with and without L-RT. Methods: We reviewed ICC patients found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT, matching them with an institutional cohort by propensity score and a National Cancer Database (NCDB) cohort by frequency technique. The median biologically effective dose (BED10) was 98 Gy (interquartile range [IQR] 80.5-97.9 Gy) for L-RT. Patients treated with other local therapies or supportive care alone were excluded. We analyzed survival with Cox proportional hazards modeling. Results: We identified 61 patients who received L-RT and 220 who received chemotherapy alone. At median follow up of 11 months after diagnosis, median OS was 9 months (95% confidence interval [CI] 8-11) and 21 months (CI 17-26) for patients receiving chemotherapy alone and L-RT, respectively. TRLF was the cause of death more often in the patients who received chemotherapy alone compared to those who received L-RT (82% vs. 47%; P=0.001). On multivariable propensity-score matched analysis, associations with lower risk of death included duration of upfront chemotherapy (hazard ratio [HR] 0.82; P=0.005) and receipt of L-RT (HR 0.40; P=0.002). The median OS from diagnosis for NCDB chemotherapy alone cohort was shorter than that of the institutional L-RT cohort (9 vs. 22 months; P<0.001). Discussion/Conclusion: For M1 ICC, L-RT associated with a lower rate of death due to TRLF and longer OS vs. those treated with chemotherapy alone. Prospective studies of L-RT in this setting are warranted.